Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatin–DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR‐3 Ovarian Cancer Cells‐Derived Xenograft Model

Aurora A kinase (Aurora A) is a serine/threonine kinase regulating control of multiple events during cell‐cycle progression. Playing roles in promoting proliferation and inhibiting cell death in cancer cells leads Aurora A to become a target for cancer therapy. It is overexpressed and associated with a poor prognosis in ovarian cancer. Improving cisplatin therapy outcomes remains an important issue for advanced‐stage ovarian cancer treatment, and Aurora A inhibitors may im-prove it. In the present study, we identified natural compounds with higher docking scores than the known Aurora A ligand through structure‐based virtual screening, including the natural com-pound fangchinoline, which has been associated with anticancer activities but not yet investigated in ovarian cancer. The binding and inhibition of Aurora A by fangchinoline were verified using cellular thermal shift and enzyme activity assays. Fangchinoline reduced viability and proliferation in ovarian cancer cell lines. Combination fangchinoline and cisplatin treatment enhanced cisplatin– DNA adduct levels, and the combination index revealed synergistic effects on cell viability. An in vivo study showed that fangchinoline significantly enhanced cisplatin therapeutic effects in OVCAR‐3 ovarian cancer‐bearing mice. Fangchinoline may inhibit tumor growth and enhance cis-platin therapy in ovarian cancer. This study reveals a novel Aurora A inhibitor, fangchinoline, as a potentially viable adjuvant for ovarian cancer therapy.